Final-Program-ATS-2023-AP.vp

156

MONDAY • MAY 22

P628 Association of Pre-pandemic CT Interstitial Lung Abnormalities and High Attenuation Areas With COVID-19 Hospitalization: The C4R Study/ J. Kim, Charlottesville, VA P629 Biomarkers of Inflammation and Aging Are Not Associated With Fibrotic-Like Pulmonary Radiographic Patterns in Severe COVID-19 Survivors/ A. Jones, New York, NY P630 Longitudinal Consistency of CT-Based Evaluation of the Volumetric Percentage of Cystic Regions in the Lungs of Patients With Lymphangioleiomyomatosis/ B.P. Matthew, Bethesda, MD P631 Oxygenation Kinetics of Patients With Pulmonary Alveolar Proteinosis During Whole Lung Lavage/ C. Yoshida, Kumamoto, Japan

P612 Characteristic Chest Computed Tomography Findings for Birt-Hogg-Dube Syndrome Indicating Requirement for Genetic Evaluation/ Y.J. Choi, Seoul, Korea, Republic of P613 Correlation of Clinical Features, Pulmonary Function, Cyst Scores and Genetic Mutations in Patients With Birt-Hogg-Dube Syndrome/ J. Khan, Dublin, Ireland P614 Outstanding Characteristics of Birt-Hogg-Dube Syndrome in Korea: Including Systematic Review/ M. Byun, Seoul, Korea, Republic of P615 Diagnostic Utility of Quantitative 3D HRCT Analysis to in Diffuse Cystic Lung Diseases/ Y. Sekimoto, Dublin, Ireland P616 Prevalence and Clinical Characteristics of Lymphangioleiomyomatosis; Less Rare Than Previously Reported?/ E. Lynn, Dublin, Ireland P617 Clinical Background of Pregnant Cases of Lymphangioleiomyomatosis/ M. Hirose, Sakai, Japan P618 Insufficient Medical Assessment for Lung Involvements in Patients With Tuberous Sclerosis Complex in Clinical Setting in Japan/ A. Masunaga, Kumamoto, Japan P619 Evaluation of Chest Radiographic Changes Visualized by Computed Tomography in Patients With the Pulmonary Langerhans Cell Histiocytosis/ E. Radzikowska, Warsaw, Poland P620 A Phase I Trial of Inhaled GM-CSF in Patients With Autoimmune Pulmonary Alveolar Proteinosis Evaluating Immunologic Responses in the Lower Respiratory Tract/ B.C. Carey, Cincinnati, OH P621 Autoimmune Pulmonary Alveolar Proteinosis: Update From the US National PAP Registry/ B.C. Carey, Cincinnati, OH P622 Cytokine Profiles Associated With Disease Severity and Prognosis of Autoimmune Pulmonary Alveolar Proteinosis/ T. Takada, Niigata, Japan P623 Spirometry in ANCA Vasculitis/ J. Clark, Chapel Hill, NC P624 Clinical Manifestations and Health Care Resource Utilization of Eosinophilic Granulomatosis With Polyangiitis (EGPA) in China: A Multi-center Retrospective Cohort Study in China (Interim Analysis)/ L. Xue, Guangzhou, China P625 Investigating Risk Factors for Immune Checkpoint Inhibitor-induced Pneumonitis in Lung Cancer Patients/ C. Zhou, Lebanon, NH P626 Investigating Pneumonitis in Cancer Patients Receiving Immune Checkpoint Inhibitors/ M. Moodabagil, Columbus, OH P627 Pharmacotherapy and Pulmonary Fibrosis Risk After SARS-CoV-2 Infection: A Prospective Nationwide Cohort Study/ R. Baccile, Chicago, IL

CLINICAL THEMATIC POSTER SESSION

B41

RISK FACTORS AND OUTCOMES FOR COPD EXACERBATIONS

9:00 a.m. - 4:15 p.m.

Walter E. Washington Convention Center Area H, Hall C (Lower Level)

Viewing: Posters will be on display for entire session

11:30-1:15

Discussion: 11:30-12:15 authors will be present for individual discussion 12:15-1:15 authors will be present for discussionwith assigned facilitators. P771 Self-report Underestimates COPD Exacerbation Frequency but Is Associated With BAL Neutrophilia and Lymphocytosis/ Y.D. Abrham, San Francisco, CA P772 Redefining Cut-points for High Symptom Burden of the Gold Classification Assists Better Prediction of Future Acute Exacerbation and Mortality Than the Conventional ABCD Classification in Patients With Chronic Obstructive Pulmonary Disease/ S. Teramoto, Hachioji-shi, Japan P773 Subtypes of Early Chronic Obstructive Pulmonary Disease Could Predict COPD Exacerbation/ N. Kim, Seoul, Korea, Republic of P774 An Analysis of the Prognosis of Chronic Obstructive Pulmonary Disease Patients With Acute Exacerbations Based on Types of Acute Respiratory Failure/ J.K. Lee, Gwangju, Korea, Republic of P775 Deep Residual Convolutional Network Predicts Future Severe Exacerbations of COPD in SPIROMICS/ H.A. Awan, Iowa City, IA P776 Saliva as a Non-invasive Specimen for COPD Evaluation/ V.J. Rangrej, Vadodara, India

ATS 2023 • Washington, DC